(DE) Implementing new tools in clinical practice
Digital health solutions for personalised prevention
John Deanfield, UK
John Deanfield, UK
When should cardiovascular medicines be discontinued?
Konstantin Krychtiuk, Austria
Konstantin Krychtiuk, Austria
Assessing the vulnerable patient using non-invasive imaging. Joint session with SCCT and BSCI
Advanced coronary CT in risk stratification
Edward Nicol, UK
Edward Nicol, UK
The role of imaging in finding the high risk patient
Michelle Williams, UK
Michelle Williams, UK
Cardio renal
Therapeutic targeting of the cardio renal axis
Maciej Tomaszewski, UK
Maciej Tomaszewski, UK
Cardiometabolic effects of SGLT2 inhibition
Paola Fioretto, Italy
Paola Fioretto, Italy
Diving further into the plaque
Using multi-omics to decipher plaque destabilisation processe
Lars Maegdefessel, Germany
Lars Maegdefessel, Germany
Antigen specific T-cell interactions in the atherosclerotic lesion
Bram Slütter, The Netherlands
Bram Slütter, The Netherlands
E-health
Using smart phones to monitor cardiovascular health
Rohan Khera, US
Rohan Khera, US
Using AI to utilise digital information in clinical practice
Calum McRae, US
Calum McRae, US
HDL
Therapeutic targeting of HDL: Should we keep trying?
John Chapman, France
John Chapman, France
Beyond reverse cholesterol: is HDL biologically relevant for what?
Laura Calabresi, Italy
Laura Calabresi, Italy
Inflammatory diseases and cardiovascular risk
Immune mediated diseases
Keith Channon, UK
Keith Channon, UK
Infectious diseases
Anette Kirabo, USA
Anette Kirabo, USA
Lp(a) – Joint session with British Pharmacological Society
Lp(a) the new target
Anne Langsted, Denmark
Anne Langsted, Denmark
Should we do cascade screening for Lp(a)?
Jamini Cegla, UK
Jamini Cegla, UK
New insights, advanced Diagnostic and Therapeutic Approaches in Atherosclerosis
The role of innate immune reprogramming in the pathophysiology of atherosclerosis – a targetable approach?
Niels Riksen, The Netherlands
Niels Riksen, The Netherlands
Functional lipid profiling of human leukocytes to improve cardiovascular risk assessment
Simon Pfisterer, Finland
Simon Pfisterer, Finland
New risk factors for atherosclerotic disease
Microparticals and microplastics in the vessels
Giuseppe Paolisso, Italy
Giuseppe Paolisso, Italy
Cardiovascular risk factors in cancer survivors
To be announced
To be announced
New targets for therapy
The crosstalk between lipid metabolism, energetic demand and thyroid hormones: pharmacological opportunities
Danilo Norata, Italy
Danilo Norata, Italy
Redefining Steatotic Liver Disease to identify novel targets to treat cardiovascular disease
Stefano Romeo, Sweden
Stefano Romeo, Sweden
Non-conventional risk factors and residual CV risk
Socio-economic disparities and cardiovascular risk
To be announced
To be announced
Ethnicity as a risk factor: How “modifiable” is it?
Ilonca Vaartjes, The Netherlands
Ilonca Vaartjes, The Netherlands
Optimisation of clinical management
Integrating multidisciplinary data for advance pheno mapping of risk factors
Evangelos Oikonomou, US
Evangelos Oikonomou, US
Using advanced phenotyping tools to enrich clinical trials: Is it time for companion diagnostics?
Jan Nilsson, Sweden
Jan Nilsson, Sweden
